1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Adnexus Therapeutics, Inc. - Product Pipeline Review - 2013

Adnexus Therapeutics, Inc. - Product Pipeline Review - 2013

  • June 2013
  • -
  • Global Markets Direct
  • -
  • 18 pages

Adnexus Therapeutics, Inc. - Product Pipeline Review - 2013


Summary


Global Market Direct’s pharmaceuticals report, “Adnexus Therapeutics, Inc. - Product Pipeline Review - 2013” provides data on the Adnexus Therapeutics, Inc.’s research and development focus. The report includes information on current developmental pipeline, complete with latest updates, and features on discontinued and dormant projects.

This report is built using data and information sourced from Global Markets Direct’s proprietary databases, Adnexus Therapeutics, Inc.’s corporate website, SEC filings, investor presentations and featured press releases, both from Adnexus Therapeutics, Inc. and industry-specific third party sources, put together by Global Markets Direct’s team.


Scope


- Adnexus Therapeutics, Inc. - Brief Adnexus Therapeutics, Inc. overview including business description, key information and facts, and its locations and subsidiaries.
- Review of current pipeline of Adnexus Therapeutics, Inc. human therapeutic division.
- Overview of pipeline therapeutics across various therapy areas.
- Coverage of current pipeline molecules in various stages of drug development, including the combination treatment modalities, across the globe.
- Product profiles for late stage and clinical stage products of Adnexus Therapeutics, Inc. with complete description of the product’s developmental history, mechanism of action, therapeutic class, target and major milestones.
- Recent updates of the Adnexus Therapeutics, Inc.’s pipeline in the last quarter.
- Key discontinued and dormant projects.
- Latest news and deals relating to the products.


Reasons to buy


- Evaluate Adnexus Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline.
- Assess the growth potential of Adnexus Therapeutics, Inc. in its therapy areas of focus.
- Identify new drug targets and therapeutic classes in the Adnexus Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas.
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps.
- Exploit collaboration and partnership opportunities with Adnexus Therapeutics, Inc..
- Avoid Intellectual Property Rights related issues.
- Explore the dormant and discontinued projects of Adnexus Therapeutics, Inc. and identify potential opportunities in those areas.

Table Of Contents

Adnexus Therapeutics, Inc. - Product Pipeline Review - 2013
Table of Contents 2
List of Tables 3
List of Figures 3
Adnexus Therapeutics, Inc. Snapshot 4
Adnexus Therapeutics, Inc. Overview 4
Key Information 4
Key Facts 4
Adnexus Therapeutics, Inc. - Research and Development Overview 5
Key Therapeutic Areas 5
Adnexus Therapeutics, Inc. - Pipeline Review 7
Pipeline Products by Stage of Development 7
Pipeline Products - Monotherapy 8
Adnexus Therapeutics, Inc. - Pipeline Products Glance 9
Adnexus Therapeutics, Inc. - Early Stage Pipeline Products 9
Preclinical Products/Combination Treatment Modalities 9
Discovery Products/Combination Treatment Modalities 10
Adnexus Therapeutics, Inc. - Drug Profiles 11
Cardiovascular Program 11
Product Description 11
Mechanism of Action 11
RandD Progress 11
Immunology Program 12
Product Description 12
Mechanism of Action 12
RandD Progress 12
Program for Additional Oncology Candidates 13
Product Description 13
Mechanism of Action 13
RandD Progress 13
Adnexus Therapeutics, Inc. - Pipeline Analysis 14
Adnexus Therapeutics, Inc. - Pipeline Products by Therapeutic Class 14
Adnexus Therapeutics, Inc. - Dormant Projects 15
Adnexus Therapeutics, Inc. - Locations And Subsidiaries 16
Head Office 16
Appendix 17
Methodology 17
Coverage 17
Secondary Research 17
Primary Research 17
Expert Panel Validation 17
Contact Us 18
Disclaimer 18

List of Tables


Adnexus Therapeutics, Inc., Key Information 4
Adnexus Therapeutics, Inc., Key Facts 4
Adnexus Therapeutics, Inc. - Pipeline by Indication, 2013 6
Adnexus Therapeutics, Inc. - Pipeline by Stage of Development, 2013 7
Adnexus Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013 8
Adnexus Therapeutics, Inc. - Preclinical, 2013 9
Adnexus Therapeutics, Inc. - Discovery, 2013 10
Adnexus Therapeutics, Inc. - Pipeline By Therapeutic Class, 2013 14
Adnexus Therapeutics, Inc. - Dormant Developmental Projects,2013 15

List of Figures


Adnexus Therapeutics, Inc. - Pipeline by Indication, 2013 6
Adnexus Therapeutics, Inc. - Pipeline by Stage of Development, 2013 7
Adnexus Therapeutics, Inc. - Monotherapy Products in Pipeline, 2013 8
Adnexus Therapeutics, Inc. - Pipeline By Therapeutic Class, 2013 14

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.